Coffee Sipping Big Board Stocks

[timhyma]

4:43 pm Pfizer receives expanded FDA approval for Ibrance In HR+, HER2 - metastatic breast cancer (PFE) :
•Co announces that the FDA has approved a new indication expanding the use of IBRANCE 125mg capsules, Pfizer's metastatic breast cancer therapy. Now IBRANCE also is approved for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy.